NCT01215435View on ClinicalTrials.gov

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

PHASE4CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms

DRUG

biphasic insulin aspart 30

Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms

Trial Locations (1)

Unknown

Tehran

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY